NOVEL RESVERATROL DITHIOCARBAMATEDERIVATIVES AS POTENTIAL NEW LEADS TARGETTING 2L98 & 4YHJ FOR CARDIOVASCULAR DISEASE
DOI:
https://doi.org/10.48047/Keywords:
Resveratrol,Dithiocarbamate, Drug likeness, AutodockVina, Discovery studio.Abstract
Phytochemicals are an attractive sourcetodiscover new leadsfor the development of novel compounds for various
diseases. Cardiovascular diseases are the principal cause of morbidity and mortality worldwide. Resveratrol is a
stilbene, which is a type of natural polyphenolic compound, used for cancer therapy, and it has shown useful effects
against cardiovascular diseases. Otherside Dithiocarbamates obtained from phytoalexins exhibited diverse
pharmacological profiles.So, we thought its worthwhile to combine two natural compounds resveratrol and
dithiocarbamate as a single entity to develop novel cardiovascular agents. All the designed compounds were
subjected to various pharmacokinetics and pharmacodynamic properties by using Insilco tools. Further Molecular
docking studies were performed to know the suitable target for the cardiovascular disease. All the compounds
obeyed Lipinski rule of five and among the series, compound 26 and 30 are more potent when compared to dock
score of the standard drug resveratrol against selected targets, G protein-coupled receptor kinase 4 (2L98), Cardiac
troponin (4YHJ) of cardiovascular disease. The present investigations concluded that the designed resveratrol
dithio derivatives are the effective and bioavailable molecules.
